Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements.
Our vision...

A trusted advisor transforming patients’ lives worldwide with pioneering molecular diagnostics

The global leader in personalized medicine
Myriad Leads Personalized Medicine Industry
Unique Scale and Expertise Creates Sustainable Competitive Advantage

Over 27 years since company was founded in 1991

1 only profitable R&D driven personalized medicine company

✔️ >3.0 million tests performed; unmatched reputation for quality

2,500 employees dedicated to the Myriad mission

>1,000 scientific publications to date; extensive research capabilities

3 expertise with all three types of biomarkers (DNA, RNA, and proteins)

1 only personalized medicine company with broad regulatory experience

>90,000 ordering physicians since inception; deep relationships

95% of U.S. payers are in-network
Myriad’s 4 in 6 Strategy

Answering patients’ four most pressing questions

Will I get a disease?
Do I have a disease?
Should I treat this disease?
How should I treat this disease?

In six medical specialties

Oncology  Dermatology
Preventive Care  Autoimmune
Urology  Neuroscience
### Critical Success Factors to Achieving Strategic Goals

<table>
<thead>
<tr>
<th>Strategic Goals</th>
<th>Critical Success Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;10% Revenue Growth</td>
<td>Stabilize hereditary cancer revenue</td>
</tr>
<tr>
<td>&gt;30% Operating Margin</td>
<td>Grow new product volume</td>
</tr>
<tr>
<td>7 Products</td>
<td>Expand reimbursement coverage for new products</td>
</tr>
<tr>
<td>&gt;$50M</td>
<td>Increase RNA kit revenue internationally</td>
</tr>
<tr>
<td>&gt;10% International Revenue</td>
<td>Improve profitability with Elevate 2020</td>
</tr>
</tbody>
</table>
Critical Success Factors to Achieving Strategic Goals

**STRATEGIC GOALS**

- **Revenue Growth**: >10%
- **Operating Margin**: >30%
- **Products**: 7
- **International Revenue**: >$50M
- **International Revenue**: >10%

**CRITICAL SUCCESS FACTORS**

- Stabilize hereditary cancer revenue
- Grow new product volume
- Expand reimbursement coverage for new products
- Increase RNA kit revenue internationally
- Improve profitability with Elevate 2020
Hereditary Cancer Business Has Been Durable
Significant Competitive Advantages Results in Continued Leadership

Hereditary Cancer Revenue (in mil.)

VOLUME
- Up 15% with flat revenue after 4 years of competition
- >3% volume growth target in 1Q18
- Third quarter in a row with YoY volume growth

PRICING
- 86% under long-term, fixed-price contracts
- Predictable pricing
A Market that Demands Perfection
Three Competitive Advantages Provide Important Differentiation

Lab accuracy:
• 85,000 base pairs with 100% accuracy
• 856 steps using 23 major technology platforms
• 100 proprietary software applications

Variant classification:
• 20 years of research; > $100M investment
• >2.5M patients tested; 50k variants identified
• 5 proprietary methods with 99.5% validity

Customer service & support:
• Over 40k ordering physicians annually
• 450 field educators
• Extensive reimbursement support
• Lifetime commitment to patients
Substantial Opportunity for Volume Growth
Highly Underpenetrated in Both Oncology and Preventive Care

U.S Oncology Market

- Patients Tested by MYGN
- Patients Not Tested
- Less than 15% penetrated

U.S Preventive Care Market

- Patients Tested by MYGN
- Patients Not Tested
- Less than 5% penetrated
riskScore Represents New Epoch in Hereditary Cancer
Broadens Already Significant Competitive Moat

Before riskScore™
>90% left without definitive risk

■ Deleterious Mutation ■ Negative

After riskScore™
100% of patients get a definitive answer

■ Deleterious Mutation ■ Unique riskScore
Cost of Performing High-Quality Test Establishes Pricing Floor
Myriad Quality Justifies Significant Price Premium

- Total cost of performing a high-quality test
- Commoditized lab operating margin
- False positives, negatives & VUS are expensive
- Myriad Quality Premium

$0
$1,000
$2,000
$3,000
Critical Success Factors to Achieving Strategic Goals

<table>
<thead>
<tr>
<th>STRATEGIC GOALS</th>
<th>CRITICAL SUCCESS FACTORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;10% Revenue Growth</td>
<td>Stabilize hereditary cancer revenue</td>
</tr>
<tr>
<td>&gt;30% Operating Margin</td>
<td>Grow new product volume</td>
</tr>
<tr>
<td>7 Products</td>
<td>Expand reimbursement coverage for new products</td>
</tr>
<tr>
<td>&gt;$50M</td>
<td>Increase RNA kit revenue internationally</td>
</tr>
<tr>
<td>&gt;10% International Revenue</td>
<td>Improve profitability with Elevate 2020</td>
</tr>
</tbody>
</table>
# Industry Leading Pipeline

*Nine Proprietary Products Sold Through Multiple Channels*

<table>
<thead>
<tr>
<th>Product</th>
<th>Clinical Question</th>
<th>Global Market Size</th>
<th>Technology</th>
<th>Distribution Channel</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>myRisk® riskScore™</em></td>
<td>Will I get cancer?</td>
<td>$4B 1.5 million patients</td>
<td>28 gene DNA sequencing &gt;80 SNPs + clinical data</td>
<td>Oncology Preventive Care Urology</td>
</tr>
<tr>
<td><em>genesight®</em></td>
<td>What antidepressant should I take?</td>
<td>$10B 5 million patients</td>
<td>12 genes multiplex PCR proprietary algorithm</td>
<td>Neuroscience Preventive Care</td>
</tr>
<tr>
<td><em>Vectra® DA</em></td>
<td>Should I change my RA treatment?</td>
<td>$3B 3 million patients</td>
<td>12 protein markers proprietary algorithm</td>
<td>Autoimmune</td>
</tr>
<tr>
<td><em>Prolaris®</em></td>
<td>How aggressively should I treat my prostate cancer?</td>
<td>$1.2B 400,000 patients</td>
<td>46 RNA markers proprietary algorithm</td>
<td>Urology</td>
</tr>
<tr>
<td><em>EndoPredict®</em></td>
<td>How aggressively should I treat my breast cancer?</td>
<td>$0.9B 350,000 patients</td>
<td>12 RNA markers proprietary algorithm</td>
<td>Oncology</td>
</tr>
<tr>
<td><em>myPath®</em></td>
<td>Is this skin lesion melanoma?</td>
<td>$0.8B 600,000 patients</td>
<td>23 RNA markers proprietary algorithm</td>
<td>Dermatology</td>
</tr>
<tr>
<td><strong>BRACAnalysis CDx®</strong></td>
<td>Should I use a PARP inhibitor to treat my cancer?</td>
<td>$6.0B 1.5 million patients</td>
<td>2 gene DNA sequencing tumor DNA sequencing proprietary algorithm</td>
<td>Oncology</td>
</tr>
</tbody>
</table>
Substantial Diversification in Testing Volumes
≈ Two-Thirds of Volume Generated by New Products

FY13
≈180,000 tests
99% Hereditary Cancer

FY17
≈600,000 tests
33% Hereditary Cancer

35%
CAGR
Early Stages of Market Adoption
Significant Opportunity For Continued Growth

- Hereditary Cancer: $4.0B
- GeneSight: $10.0B
- Vectra DA: $3.0B
- Prolaris: $1.2B
- EndoPredict: $0.9B
- myPath Melanoma: $0.8B
- CDx: $6.0B
### Critical Success Factors to Achieving Strategic Goals

<table>
<thead>
<tr>
<th>STRATEGIC GOALS</th>
<th>CRITICAL SUCCESS FACTORS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>&gt;10%</strong> Revenue Growth</td>
<td>Stabilize hereditary cancer revenue</td>
</tr>
<tr>
<td><strong>&gt;30%</strong> Operating Margin</td>
<td>Grow new product volume</td>
</tr>
<tr>
<td>7 Products</td>
<td>Expand reimbursement coverage for new products</td>
</tr>
<tr>
<td><strong>&gt;$50M</strong></td>
<td>Increase RNA kit revenue internationally</td>
</tr>
<tr>
<td><strong>&gt;10%</strong> International Revenue</td>
<td>Improve profitability with Elevate 2020</td>
</tr>
</tbody>
</table>
Additional Reimbursement is a Growth Multiplier
Fully Reimbursed New Product Revenue is $670 Million

Near Term Drivers

<table>
<thead>
<tr>
<th>Product</th>
<th>U.S. Coverage</th>
<th>Current Revenue Run Rate at Full Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hereditary Cancer</td>
<td></td>
<td>≈$500M</td>
</tr>
<tr>
<td>EndoPredict</td>
<td></td>
<td>$10M</td>
</tr>
<tr>
<td>Prolaris</td>
<td></td>
<td>$50M</td>
</tr>
<tr>
<td>Vectra DA</td>
<td></td>
<td>$100M</td>
</tr>
<tr>
<td>GeneSight</td>
<td></td>
<td>$500M</td>
</tr>
<tr>
<td>myPath Melanoma</td>
<td></td>
<td>$10M</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NCCN Guidelines
ACR Guidelines
Demonstration Studies
1,200 Patient Clinical Study Demonstration Studies

GeneSight® Psychotropic

Proprietary Combinatorial Pharmacogenomic Test

Data on 55 antidepressants covering 95% of prescriptions for depression, bipolar disorder, anxiety and schizophrenia.

- Use As Directed
  - Likely well tolerated and efficacious
- Moderate Gene-Drug Interaction
  - Dosing change may improve efficacy/tolerability
- Significant Gene-Drug Interaction
  - Poorly tolerated and/or efficacy concerns

331,776 unique GeneSight report genetic combinations and medication recommendations
# Phase 3 GeneSight RCT Study – Class A Evidence

## Overview
- Randomized, 8 week double-blind, controlled evaluation followed by an open-label follow-up period of an additional 16 weeks
- Compare the patient response to psychotropic treatments in a GeneSight-guided arm (GS) vs. a Treatment as Usual (TAU) arm

## Population
- ~1,200 patients, 18 years or older
- Diagnosed with moderate to severe depression
- Inadequate response to at least 1 psychotropic treatment

## Arms
- GeneSight – GS
- Treatment As Usual – TAU (any medication, multiple medication, any doses)

## Endpoint
- HAMD-17 Scores compared at baseline to 8 week time point
- 3 calculations: Remission, Response, Symptom Improvement

## Investigators

### GeneSight Study Significant for Most Important Endpoints

**Beginning Discussions With Commercial Payers**

<table>
<thead>
<tr>
<th>Study endpoint</th>
<th>What it Means</th>
<th>Study Result</th>
<th>Importance to Clinicians and Payers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remission</td>
<td>Patient no longer depressed</td>
<td>Highly statistically significant (p&lt;0.01)</td>
<td>Very important</td>
</tr>
<tr>
<td>hard to achieve</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Response</td>
<td>Patient feels a lot better</td>
<td>Highly statistically significant (p=0.01)</td>
<td>Very important</td>
</tr>
<tr>
<td>difficult to achieve</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptom Improvement</td>
<td>Patient feels somewhat better</td>
<td>Approaching statistical significance (p=0.1)</td>
<td>Meaningful</td>
</tr>
<tr>
<td>most likely to achieve</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Remission, Response, and Symptom Improvement were durable and continued to improve over the 24 week study period
- 40 antidepressant FDA registration studies in the last 20 years:
  - All were compared to placebo, not active drug like GeneSight
  - Only 13% showed statistical significance for Remission
  - Only 33% showed statistical significance for Response
### Critical Success Factors to Achieving Strategic Goals

<table>
<thead>
<tr>
<th>STRATEGIC GOALS</th>
<th>CRITICAL SUCCESS FACTORS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>&gt;10%</strong> Revenue Growth</td>
<td>Stabilize hereditary cancer revenue</td>
</tr>
<tr>
<td><strong>&gt;30%</strong> Operating Margin</td>
<td>Grow new product volume</td>
</tr>
<tr>
<td>7 Products</td>
<td>Expand reimbursement coverage for new products</td>
</tr>
<tr>
<td><strong>&gt;$50M</strong></td>
<td>Increase RNA kit revenue internationally</td>
</tr>
<tr>
<td><strong>&gt;10%</strong> International Revenue</td>
<td>Improve profitability with Elevate 2020</td>
</tr>
</tbody>
</table>
### International Growth Focused in Major Geographies
Kit Products Appeal to Existing Business Models

<table>
<thead>
<tr>
<th>COUNTRIES</th>
<th>KITS</th>
<th>REFERENCE TESTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct Sales: EU5 + Canada</td>
<td>RNA (platform partner): • EndoPredict • Prolaris • myPath Melanoma</td>
<td>DNA (multiple platforms): Companion Diagnostics</td>
</tr>
<tr>
<td>Distributor China, Japan, Brazil, and others</td>
<td>Protein (platform partner): • Vectra DA • myPath Bipolar</td>
<td></td>
</tr>
</tbody>
</table>

*Copyright © 2018 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.*
EndoPredict Well Positioned For Continued Growth
Major Reimbursement Catalysts Should Drive Market Traction

Focus – EU5 & Canada

UK: NICE Recommendation expected in 2H FY18

Germany: Increasing sites registered for reimbursement

Switzerland: Broad coverage

Italy: Coverage decision anticipated in FY18

Canada: Ontario reimbursement; additional provincial decisions expected in FY18

France: Broad coverage
Critical Success Factors to Achieving Strategic Goals

<table>
<thead>
<tr>
<th>STRATEGIC GOALS</th>
<th>CRITICAL SUCCESS FACTORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue Growth (＞10%)</td>
<td>Stabilize hereditary cancer revenue</td>
</tr>
<tr>
<td>Operating Margin (＞30%)</td>
<td>Grow new product volume</td>
</tr>
<tr>
<td>7 Products</td>
<td>Expand reimbursement coverage for new products</td>
</tr>
<tr>
<td>International Revenue (＞$50M)</td>
<td>Increase RNA kit revenue internationally</td>
</tr>
<tr>
<td>International Revenue (＞10%)</td>
<td>Improve profitability with Elevate 2020</td>
</tr>
</tbody>
</table>
Launching Elevate 2020

Goal of Achieving $50M in Incremental Operating Profit by FY20

FY18:
16 projects identified
$17M in cost savings

FY19:
15 projects identified
$24M in cost savings

FY20 and beyond:
Additional project evaluations
Additional cost savings

Goal:
$50M in incremental operating profit by FY20
Financial Outlook
Additional Reimbursement Transformative
With Full Reimbursement FY17 Revenue >$1.1B, Operating Margins >40%

- > 40% adjusted operating margin
- > $300 million in free cash flow
- >$4.00 per share in adjusted EPS
## Potential Catalysts in Fiscal Year 2018

### Multiple Possibilities for Material Upsides

<table>
<thead>
<tr>
<th>Product</th>
<th>Potential Catalyst</th>
<th>Potential Timing</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>myRisk®</td>
<td>Better Volume Growth</td>
<td>FY18</td>
<td>&gt;3% growth in 1Q18</td>
</tr>
<tr>
<td>BRACAnalysis®</td>
<td>Metastatic Breast Cancer Indication</td>
<td>2H FY18</td>
<td>FDA submission complete; expect decision in 3Q18</td>
</tr>
<tr>
<td>genesight®</td>
<td>Additional Reimbursement</td>
<td>FY18</td>
<td>Successful prospective study</td>
</tr>
<tr>
<td>Vectra®</td>
<td>ACR Guidelines &amp; Reimbursement</td>
<td>2H FY18</td>
<td>Increased Medicare rate under PAMA</td>
</tr>
<tr>
<td>Prolaris®</td>
<td>Additional Reimbursement</td>
<td>FY18</td>
<td>Increased Medicare rate under PAMA</td>
</tr>
<tr>
<td>EndoPredict®</td>
<td>Increased Adoption in U.S.</td>
<td>FY18</td>
<td>2% market share run rate at end of 1Q18</td>
</tr>
<tr>
<td>myPath®</td>
<td>Additional Reimbursement</td>
<td>FY18</td>
<td>New NCCN guidelines</td>
</tr>
</tbody>
</table>
# Uses of Cash

<table>
<thead>
<tr>
<th>Uses of Cash</th>
<th>Current Focus</th>
<th>GOAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D</td>
<td>10% of revenue</td>
<td>Invest in late-stage reimbursement studies</td>
</tr>
<tr>
<td>M&amp;A</td>
<td>Integration of Assurex and Sividon Acquisitions</td>
<td>• $100M in potential milestones next two years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Assess opportunities that fit 4in6 strategy with potential for near-term accretion</td>
</tr>
<tr>
<td>Debt Repayment</td>
<td>$74M</td>
<td>Reduce with excess free cash flow</td>
</tr>
<tr>
<td>Share Repurchase</td>
<td>$174M authorized</td>
<td>Opportunistic open market purchases</td>
</tr>
</tbody>
</table>
Worldwide Leader in Personalized Medicine

• We are entering the golden age for personalized medicine
• Molecular diagnostics are the keystone for improving patient outcomes while eliminating waste in healthcare spending
• Myriad is the pioneer of “research-based” and “education-centric” business model for molecular diagnostics
• We are the best positioned company to lead this revolution in healthcare